• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    How Is The Market Feeling About Jazz Pharmaceuticals?

    7/15/24 3:00:27 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email

    Jazz Pharmaceuticals's (NYSE:JAZZ) short percent of float has risen 4.88% since its last report. The company recently reported that it has 2.68 million shares sold short, which is 5.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.93 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Jazz Pharmaceuticals Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Jazz Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing Jazz Pharmaceuticals's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Jazz Pharmaceuticals's peer group average for short interest as a percentage of float is 6.06%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $JAZZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    11/24/2025$188.00Buy → Neutral
    UBS
    7/15/2025$152.00Buy
    Deutsche Bank
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    6/5/2024$169.00Buy
    Goldman
    1/3/2024$160.00Outperform
    Robert W. Baird
    More analyst ratings

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

    DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.   Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be availa

    2/10/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

    Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (NASDAQ:JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer's ongoing Beamion-BCGC1 trial, evaluating the combination of Boehringer's zongertinib and Jazz's zanidatamab in breast cancer. Despite significant progress in HER2-targeted therapies, HER2-positive breast cancer remains an aggressive subtype, ac

    1/12/26 7:05:00 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

    Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env

    1/8/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jazz Pharma downgraded by UBS with a new price target

    UBS downgraded Jazz Pharma from Buy to Neutral and set a new price target of $188.00

    11/24/25 8:15:18 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Jazz Pharma with a new price target

    Deutsche Bank initiated coverage of Jazz Pharma with a rating of Buy and set a new price target of $152.00

    7/15/25 8:41:59 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharma upgraded by UBS with a new price target

    UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously

    3/7/25 8:10:15 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Technical Operations Henderson Mary Elizabeth was granted 10,116 units of Ordinary Shares, increasing direct ownership by 52% to 29,624 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    1/21/26 8:45:26 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Accounting Officer Carr Patricia was granted 2,370 units of Ordinary Shares, increasing direct ownership by 34% to 9,382 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    1/21/26 8:39:01 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Legal Officer Patil Neena M was granted 8,852 units of Ordinary Shares and returned $560,549 worth of Ordinary Shares to the company (3,275 units at $171.16), increasing direct ownership by 12% to 53,339 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    1/21/26 8:36:54 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    SEC Filings

    View All

    Jazz Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)

    1/12/26 9:01:17 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    11/26/25 5:37:21 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    11/20/25 4:05:34 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    5/13/25 6:51:34 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/5/24 7:28:40 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/13/24 5:07:58 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    9/11/23 1:33:44 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/9/23 11:25:15 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    View All

    Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

    DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.   Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be availa

    2/10/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

    – Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex®, Xywav® and the launch of Modeyso – DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the third quarter of 2025 and updated financial guidance for 2025. "Achieving the highest revenue quarter in Jazz's history speaks to the strength of our diversified portfolio and the outstanding performance of our team. We were pleased to once again deliver solid executio

    11/5/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

    DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss 2025 third quarter financial results and provide a business and financial update. Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A rep

    10/22/25 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    View All

    Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

    Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env

    1/8/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.  "We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial su

    10/28/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

    – Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in t

    7/10/25 7:30:00 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care